Here's an interesting hard sell letter to CVM shareholders. I'm sure Rick will enjoy it.
Marc
-----------------------------------
Dear Fellow Shareholders:
A major impact on cancer therapy is achieved when a new treatment
significantly increases the survival of cancer patients. With this goal
in mind, a great deal of work is being conducted to increase the success
rate of surgery, radiation and chemotherapy, but, so far, the results do
not point to a breakthrough. Immunotherapy is designed to mobilize the
immune system in the fight against cancer, but immunotherapy has its
limitations too. We believe that our drug, Multikine(R), is a first in a
new class of drug that works by both enhancing radiation/chemotherapy and
activating the immune response against the cancer. We further believe
that this dual action with Multikine, added to existing first line cancer
therapy, may ultimately allow us to increase the success rate of the
first cancer treatment.
We expect to have multiple peer-reviewed scientific publications of data
from our clinical trials with Multikine published during the next
12 months, including one before the end of this year. These new findings
will help you understand why Multikine immunotherapy is so unique and
different, and holds out so much promise for the treatment of cancer. We
ask you to take the time to read those papers in detail and to ask
yourself the following question: "If I was diagnosed with cancer, would
I want Multikine to be added to my regular treatment?" Of all of the
experts who have reviewed the data for CEL-SCI under a secrecy agreement
to date, everyone said yes. We would, too.
We hope that after the publication of our data the readers will allow
themselves to think differently about the treatment of cancer. A new
approach is needed. We believe that Multikine added to the current first
line therapy may very well provide the breakthrough needed for the
treatment of cancer.
Thank you for supporting us.
Sincerely,
Geert Kersten Maximilian de Clara
Chief Executive Officer President |
